Brenus Pharma
Description
Brenus Pharma is a French clinical-stage biotech developing a pioneering technology platform, Stimulated-Tumor-Cell (STC).
STC is designed to generate 'off-the-shelf' , first-in-class therapeutic cancer vaccine leading the way to a new precision medicine in immuno-oncology.
Brenus Pharma is on the brink of a breakthrough and will start its First in Human study in 2024 in colorectal cancer, 2nd cause of cancer-related deaths worldwide. We are building a strong portfolio in solid tumors, leveraging our patented STC platform, to change a paradigm in oncology.